• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.伴有inv(16)的核心结合因子急性髓系白血病：高龄和高白细胞计数是治疗失败的危险因素。
Int J Lab Hematol. 2021 Feb;43(1):e19-e25. doi: 10.1111/ijlh.13338. Epub 2020 Sep 14.
2
Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).在卡萨布兰卡（摩洛哥）接受inv 16治疗的急性髓系白血病成年患者的特征。
Bull Cancer. 2018 Jun;105(6):552-555. doi: 10.1016/j.bulcan.2018.03.003. Epub 2018 May 4.
3
Acute myeloid leukemia with cryptic CBFB-MYH11 type D.隐匿性CBFB-MYH11 D型急性髓系白血病
Int J Clin Exp Pathol. 2013;6(1):110-2. Epub 2012 Nov 20.
4
Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.伴有核心结合因子β异常的急性髓系白血病的新旧预后因素。
Am J Hematol. 2013 Jul;88(7):594-600. doi: 10.1002/ajh.23461. Epub 2013 Jun 5.
5
BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.从诊断到造血干细胞移植：连续监测伴有核心结合因子阳性 AML 的成人患者中的 BAALC 和 WT1 表达。
Eur J Haematol. 2013 Aug;91(2):112-21. doi: 10.1111/ejh.12142. Epub 2013 Jun 28.
6
Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.CBFβ-SMMHC急性髓系白血病的分子基础与靶向抑制
Adv Exp Med Biol. 2017;962:229-244. doi: 10.1007/978-981-10-3233-2_15.
7
Cryptic insertion of CBFB into MYH11 leading to a type D fusion in acute myeloid leukemia with normal karyotype.CBFB隐匿插入到MYH11中导致核型正常的急性髓系白血病中的D型融合。
Int J Lab Hematol. 2022 Feb;44(1):e36-e39. doi: 10.1111/ijlh.13694. Epub 2021 Sep 6.
8
Incidental identification of inv(16)(p13.1q22)/- variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.通过常规白血病易位谱筛查偶然发现 1 例治疗相关性急性髓系白血病患者中的 inv(16)(p13.1q22)/- 变异转录本：对诊断和治疗的影响。
Cold Spring Harb Mol Case Stud. 2021 Jun 11;7(3). doi: 10.1101/mcs.a006084. Print 2021 Jun.
9
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.核心结合因子急性髓系白血病中c-KIT突变的患病率及预后意义：来自中国单一中心的一项全面大规模研究
Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6.
10
[Relationship between RAD51-g135C and XRCC3-C241T polymorphisms and prognosis of inv (16)/ t(16;16) (CBFbeta-MYH11) acute myeloid leukemia].RAD51基因g135C多态性与XRCC3基因C241T多态性与inv(16)/t(16;16)(CBFβ-MYH11)急性髓系白血病预后的关系
Zhonghua Xue Ye Xue Za Zhi. 2011 Jul;32(7):433-8.

引用本文的文献

1
Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.儿童核心结合因子急性髓系白血病的分子遗传学分析
Ther Adv Hematol. 2025 Apr 16;16:20406207251330064. doi: 10.1177/20406207251330064. eCollection 2025.
2
Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).CBF 儿科 AML 伴 t(8;21)患者的预后因素和结果与 inv(16)患者不同。
BMC Cancer. 2023 May 25;23(1):476. doi: 10.1186/s12885-023-10965-5.
3
Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia.急性髓系白血病细胞衰老相关免疫原性特征及免疫治疗预测的综合分析
Front Pharmacol. 2022 Sep 26;13:987398. doi: 10.3389/fphar.2022.987398. eCollection 2022.
4
Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.靶向 inv(16) 急性髓系白血病中的 miR-126 抑制白血病发生和白血病干细胞维持。
Nat Commun. 2021 Oct 22;12(1):6154. doi: 10.1038/s41467-021-26420-7.
5
How to Improve Prognostication in Acute Myeloid Leukemia with Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring.如何通过融合转录本改善急性髓系白血病的预后：聚焦分子可测量残留病（MRD）监测的作用
Biomedicines. 2021 Aug 3;9(8):953. doi: 10.3390/biomedicines9080953.
6
Emerging therapies for inv(16) AML.用于 inv(16) AML 的新兴疗法。
Blood. 2021 May 13;137(19):2579-2584. doi: 10.1182/blood.2020009933.

本文引用的文献

1
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).伴 t(8;21)的核心结合因子急性髓系白血病：危险因素和一种新的评分系统（I-CBFit）。
Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.
2
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.核心结合因子急性髓系白血病的全面突变谱分析
Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.
3
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.具有复杂核型、年龄较大和一线治疗剂量强度降低与具有长期随访的核心结合因子急性髓系白血病患者的不良生存相关。
Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.
4
Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.核心结合因子急性髓系白血病的新兴诊断与治疗方法
Curr Opin Hematol. 2015 Mar;22(2):85-91. doi: 10.1097/MOH.0000000000000124.
5
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.核心结合因子急性髓系白血病：年龄、白细胞计数、分子发现和微小残留病的影响。
Eur J Haematol. 2013 Sep;91(3):209-218. doi: 10.1111/ejh.12130. Epub 2013 Jul 25.
6
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).伴有 inv(16) 或 t(16;16) 的急性髓系白血病中的二次遗传病变：德国-奥地利急性髓系白血病研究组（AMLSG）的研究。
Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.
7
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.中危急性髓系白血病中白细胞计数的预后影响：突变型 NPM1 和 FLT3-ITD 的相关性。
Haematologica. 2011 Sep;96(9):1310-7. doi: 10.3324/haematol.2011.040592. Epub 2011 May 23.
8
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.核心结合因子急性髓系白血病伴t(8;21)患者的预后因素及结局与伴inv(16)患者不同：一项癌症与白血病B组研究
J Clin Oncol. 2005 Aug 20;23(24):5705-17. doi: 10.1200/JCO.2005.15.610.
9
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.基于个体患者数据的16至60岁核心结合因子急性髓系白血病患者的荟萃分析：德国急性髓系白血病协作组的一项调查
J Clin Oncol. 2004 Sep 15;22(18):3741-50. doi: 10.1200/JCO.2004.03.012. Epub 2004 Aug 2.
10
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.inv(16)/t(16;16)急性髓系白血病（AML）的预后：来自法国AML协作组的110例病例调查
Blood. 2003 Jul 15;102(2):462-9. doi: 10.1182/blood-2002-11-3527. Epub 2003 Mar 20.

Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.

作者信息

Ustun Celalettin, Morgan Elizabeth A, Ritz Ethan M, Vestergaard Hanne, Pullarkat Sheeja, Kluin Philip M, Ohgami Robert, Baughn Linda B, Kim Young, Ku Nam K, Czuchlewski David, Boe Møller Michael, Schiefer Ana-Iris, Mrózek Krzysztof, Horny Hans-Peter, George Tracy I, Kielsgaard Kristensen Thomas, Beck Todd, Nathan Sunita, Arana Yi Cecilia, Yeung Cecilia, Pullarkat Vinod, Gotlib Jason, Akin Cem, Kohlschmidt Jessica, Salhotra Amandeep, Soma Lori, Chen Dong, Han Se Y, Cho Christina, Sperr Wolfgang, Broesby-Olsen Sigurd, Linden Michael A, Dolan Michelle, Hoermann Gregor, Hornick Jason L, Bloomfield Clara, Nakamura Ryo, Joachim Deeg H, Litzow Mark R, Borthakur Gautam, Weisdorf Daniel, Huls Gerwin, Perales Miguel-Angel, Valent Peter, Marcucci Guido

机构信息

Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

出版信息

Int J Lab Hematol. 2021 Feb;43(1):e19-e25. doi: 10.1111/ijlh.13338. Epub 2020 Sep 14.

DOI:10.1111/ijlh.13338
PMID:32926565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8434847/
Abstract
摘要